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previous works linked low sodium concentration with mortality risk in cancer. We aimed at weighing the 
prognostic impact of hyponatremia in all consecutive patients with metastatic solid tumors admitted 
in a two-years period at our medical oncology department. patients were included in two cohorts 
based on serum sodium concentration on admission. A total of 1025 patients were included, of whom 
279 (27.2%) were found to be hyponatremic. The highest prevalence of hyponatremia was observed 
in biliary tract (51%), prostate (45%) and small-cell lung cancer (38.9%). With a median follow-up of 
26.9 months, median OS was 2 months and 13.2 months for the hyponatremia versus control cohort, 
respectively (HR, 2.65; P < 0.001). In the multivariable model, hyponatremia was independently 
associated with poorer OS (HR, 1.66; P < 0.001). According to the multivariable model, a nomogram 
system was developed and validated in an external set of patients. We weighed over time the influence 
of hyponatremia on survival of patients with metastatic solid tumors and pointed out the possibility 
to exploit serum sodium assessment to design integrated prognostic tools. our study also highlights 
the need for a deeper characterization of the biological role of extracellular sodium levels in tumor 
development and progression.
Hyponatremia, as defined by a serum sodium concentration lower than 135 mEq/L, is the electrolyte alteration 
most frequently found in hospitalized patients, and a common finding at admission in Oncology Units1,2. In 
cancer patients, many overlapping factors can contribute to the onset of hyponatremia, including paraneoplastic 
syndromes (both cerebral salt wasting and syndrome of inappropriate antidiuretic hormone secretion, SIADH), 
clinical events (e.g. vomiting, diarrhea or bleeding) or syndromes (e.g., cachexia), anticancer treatments (cyto-
toxic agents, targeted therapies or immune checkpoint inhibitors) and general medications (e.g. opioids, diuretics 
and antidepressants)3–7. Albeit underdiagnosed, SIADH is one of the most common causes of euvolemic hypon-
atremia, especially in patients with small cell lung cancer (SCLC)8. Non-small cell lung cancer (NSCLC), breast 
cancer (BC), head and neck cancer (HNC), and colorectal cancer (CRC) are the non-hematologic malignancies 
most frequently associated with hyponatremia3,8. Regardless of the etiology, hyponatremia has been associated 
with high mortality risk both in cancer and non-cancer patients9–12, as well as with lower progression-free sur-
vival (PFS) and poorer response to treatments in patients with different malignancies13–17. Although previous 
studies showed an association between hyponatremia and poor patients’ survival in the metastatic setting11,18–20, 
the conclusions of these studies are intrinsically biased by small sample size, inclusion of patients with different 
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tumor stages, or restriction to terminally ill patients. Here, we aimed at weighing the prognostic impact of hypon-
atremia in a large cohort of hospitalized patients with advanced solid tumors.
Methods
patients’ population. Electronic registries of Fondazione IRCCS Istituto Nazionale dei Tumori of Milan 
were retrospectively searched in order to identify all patient admissions to the Medical Oncology department 
from January 1st 2014 to December 31st 2015. All admitted patients with advanced solid tumors were eligible and 
screened for serum sodium concentration on the admission day as part of a prospective departmental registry 
approved by the Institutional Review Board of Fondazione IRCCS Istituto Nazionale dei Tumori di Milano and 
according to the ethical principles for medical research involving human subjects adopted in the Declaration of 
Helsinki. All the participants signed an informed consent. Patients with at least one finding of hyponatremia at 
admission were included in the hyponatremia cohort. For patients presenting more than one hyponatremic event 
at admission during the study period, we only considered the hospitalization when hyponatremia was detected 
for the first time. Patients with no evidence of hyponatremia during any admission were included in the control 
cohort: in such cases, clinical and biological data regarding the first hospitalization occurring during the study 
period were recorded. Hyponatremia was classified as mild (130–134 mEq/L), moderate (125–129 mEq/L) or 
severe (<125 mEq/L) based on serum sodium concentration at admission, and in hypovolemic, hypervolemic 
or euvolemic based on the presence of causes of volume depletion or volume overload and based on the fluid 
status21. The following patient and tumor characteristics were collected: age, gender, ECOG PS, tumor histology, 
number and type of metastatic sites, number of previous lines of treatment, length of hospitalization and the pres-
ence of serum calcium or potassium alterations at admission. The following additional information was collected 
for hyponatremic patients: presence of factors contributing to the onset of hyponatremia, SIADH diagnosis and 
serum sodium concentration at discharge.
Statistical analyses. Descriptive statistics were used to summarize baseline and hyponatremic patient char-
acteristics, like counts and percentages for categorical variables, medians and interquartile ranges (IQRs) for con-
tinuous variables. We also assessed the frequency of hyponatremia among specific patient subgroups by means 
of Pearson’s chi square tests.
Overall survival (OS) time was calculated from the date of hospitalization to the date of death for any cause, 
with censoring for patients alive at the date of last follow up information. The Kaplan-Meier method was used for 
estimation of OS curves and related descriptive statistics, while the reverse Kaplan-Meier method described by 
Schemper and Smith22 was used for follow-up quantification. OS analysis relied on extensive use of Cox propor-
tional hazards uni- and multivariable regression models according to a three-step strategy. Generalized boosted 
regression was used first for exploratory purposes, that is, to screen out irrelevant variables in terms of association 
with OS23. This tree-based regression approach, which is able to incorporate observations with partially missing 
data, also provided guidance for the detection of nonlinear effects and possible interactions among covariates, 
which was useful for the subsequent phase of analysis. As conventionally done, the variables with a relative influ-
ence lower than 1 were discarded, while the remaining variables were entered into a multivariable Cox pro-
portional hazards regression model and selected with an Akaike Information Criterion (AIC)-based backward 
procedure24. The final step was addressed to fine-tune the model and visually describe the effect of prognostic fac-
tors through the use of nomograms. Cox model results were summarized using hazard ratios (HRs), together with 
the corresponding 95% confidence intervals (CI) and Wald’s p values, while model performance was assessed 
in terms of raw and bootstrap adjusted discrimination (Harrell’s c index)25. Nomogram external validation was 
performed on updated data from a cohort of 87 patients previously reported by Berardi et al.19. For this purpose, 
the validation series was stratified on the basis of nomogram predicted OS and stratum-specific Kaplan-Meier 
curves were estimated and compared with the logrank test. Furthermore, the overall agreement between observed 
and predicted deaths was assessed by means of a Poisson linear regression model. The modeling tools adopted 
were, respectively, Cox regression and linear models for normally distributed variables. Statistical analyses were 
carried out with SAS (version 9.4, SAS Institute, Cary, NC, USA) and R software (version 3.4.2, R Foundation 
for Statistical Computing, Vienna, Austria). Statistical significance was set at the conventional 5% two-sided 
threshold.
Results
patients’ characteristics. Overall, 1025 patients hospitalized at our department from January 2014 to 
December 2015 were included, of whom 279 (27.2%) presented at least one finding of hyponatremia at admission 
during the study period. Supplementary Figure S1 and Supplementary Table S1 depict the CONSORT diagram 
of patients’ selection and their characteristics, respectively. The most represented histologies in our series were 
CRC (17.2%), NSCLC (17.0%), BC (16.5%) and gastroesophageal cancer (GEC) (8.5%). The highest prevalence 
of hyponatremia was observed in biliary tract cancer (BTC) (25 out of 49 patients, 51.0%), prostate cancer (PC) (9 
out of 20 patients, 45.0%) and SCLC (14 out of 36 patients, 38.9%) (Table 1). Hyponatremia was positively associ-
ated with male gender, worse ECOG PS, higher number of metastatic sites, presence of liver, bone, brain, adrenal 
and lymph nodes metastases, higher number of previous treatment lines, and calcium or potassium imbalances 
(Table 1) while no association was observed between hyponatremia and age. Notably, patients in the hypona-
tremia cohort had a longer median length of hospitalization (8 days; IQR, 5 to 12 months) compared to patients 
in the control cohort (4 days; IQR, 3–8 months) (P < 0.001).
Specific characteristics of hyponatremic patients are shown in Table 2. Severe hyponatremia was detected in 12 
(4.3%) out of 279 hyponatremic patients. An etiological diagnosis of hypovolemic (with coexisting volume deple-
tion) or hypervolemic (with coexisting volume overload) hyponatremia was clearly established in 55 (19.7%) 
and 13 (4.7%) patients, respectively, while in the remaining 211 patients (75.6%) hyponatremia was considered 
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Characteristics N % 95% CI P
Gender <0.001
Male 160 32.3 28.2–36.6
Female 119 22.5 19–26.3
Age (years) 0.3
<65 158 28.5 24.8–32.4
≥65 121 25.7 21.9–30
ECOG PS <0.001
0 33 12.1 8.5–16.6
1 100 22.7 18.9–26.9
2 51 49 39.1–59
3-4 93 60.4 52.2–68.2
Histology <0.001
CRC 39 22.2 16.3–29
NSCLC 44 25.3 19–32.4
BC 35 20.7 14.9–27.6
GEC 30 34.5 24.6–45.4
Melanoma 19 32.2 20.6–45.6
PaC 18 34 21.5–48.3
BTC 25 51 36.3–65.6
RCC 11 28.2 15–44.9
SCLC 14 38.9 23.1–56.5
NET 7 25 10.7–44.9
PC 9 45 23.1–68.5
Other 28 20.7 14.3–28.6
Metastatic sites (N) <0.001
1 62 19.2 15.1–23.9
2 77 24.8 20.1–29.9
≥3 140 35.8 31.1–40.8
Liver metastases 0.001
No 133 23.3 19.9–26.9
Yes 146 32.2 27.9–36.8
Lung metastases 0.5
No 175 26.6 23.2–30.1
Yes 104 28.4 23.9–33.3
Bone metastases 0.01
No 175 24.9 21.7–28.2
Yes 104 32.4 27.3–37.8
Brain metastases 0.02
No 238 26.1 23.3–29.1
Yes 41 36.3 27.5–45.9
Adrenal metastases 0.03
No 252 26.4 23.6–29.3
Yes 27 38 26.8–50.3
Pleural metastases 0.1
No 245 26.5 23.7–29.5
Yes 34 33.7 24.6–43.8
Lymphnodal metastases <0.001
No 96 19 15.7–22.7
Yes 183 35.2 31.1–39.5
Previous lines of treatment (N) <0.001
0 115 22.5 18.9–26.3
1–2 116 36.3 31–41.8
≥3 48 24.9 18.9–31.6
Days of hospitalization <0.001
≤5 89 16.8 13.7–20.3
>5 190 38.4 34.1–42.8
Other electrolyte imbalances <0.001
Continued
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to be euvolemic. Among patients with euvolemic hyponatremia, a diagnosis of SIADH was clearly established 
only in 5 (1.8% of the entire hyponatremia cohort). We found that 103 hyponatremic patients (36.9%) were 
receiving opioids when hyponatremia was detected, while concomitant use of diuretics and antidepressant drugs 
was observed in 29 (10.4%) and 20 (7.2%) patients, respectively. Specific treatments for hyponatremia consisted 
in fluid restriction in 79 patients (28.3%), administration of isotonic and hypertonic saline in 77 (27.6) and 118 
patients (42.3%), respectively; finally, tolvaptan was prescribed to 5 (1.8%) patients with an established diagnosis 
of SIADH. A normalization in sodium level at discharge was observed in 113 patients (43.0%) with no differences 
in terms of normalization rate according to the type of hyponatremia (hypovolemic, hypervolemic or euvolemic) 
(P = 0.23). 44 patients (15.8%) were readmitted with recurrence or persistence of hyponatremia during the study 
period. Normalization in sodium level at discharge was negatively associated with the chance of recurrence or 
persistence of hyponatremia (odds ratio, 0.36; 95% CI, 0.17–0.76; P = 0.008).
impact of hyponatremia on overall survival. With a median follow-up of 26.9 months (IQR, 19.8–35.6 
months), death for all causes was recorded in 241 (86.4%) patients in the hyponatremia cohort and 450 (60.3%) 
in the control cohort. Median overall survival (OS) was 2 months (IQR, 0.7–8.2 months) and 13.2 months 
(IQR, 4.1–35.4 months) for hyponatremic versus control patients, respectively (HR, 2.65; 95% CI, 2.26–3.11; 
P < 0.001) (Fig. 1 and Supplementary Table S2). Survival curves and HRs of patients with the four most repre-
sented tumor histologies in our study population are shown in Fig. 2 and Supplementary Table S2. When the 
weight of each variable on overall survival was assessed, ECOG PS and histology showed the greatest relative 
influence (Supplementary Table S3). In the multivariable model (Table 3), all covariates (age, ECOG PS, histol-
ogy, presence of liver, bone and brain metastases, number of completed lines of treatment and other electrolyte 
imbalances) were significantly associated with OS. Of note, hyponatremia was associated with poorer OS inde-
pendently from other variables (HR, 1.66; 95% CI, 1.38–2.01; P < 0.001). Accordingly, adjusted median OS for 
the hyponatremia versus control cohort was 4.7 months (IQR, 1.5–15.6 months) and 9.2 months (IQR, 2.4–32.6 
months) (Fig. 1). Adjusted survival curves and HRs for the four most represented histologies are shown in Fig. 2 
and Supplementary Table S2.
Characteristics N % 95% CI P
Calcium 42 35.6 27–44.9
Potassium 36 37.9 28.1–48.4
Both 22 40 27–54.1
None 179 24 21–27.2
Table 1. Prevalence of hyponatremia according to patients’ characteristics. Abbreviations. IQR: interquartile 
range; NA: not available; CRC: colorectal cancer; NSCLC: non-small cell lung cancer; BC: breast cancer; GEC: 
gastroesophageal cancer; PaC: pancreatic cancer; BTC: biliary tract cancer; RCC: renal cell carcinoma; SCLC: 
small-cell lung cancer; NET: neuroendocrine tumor; PC: prostate cancer.
Characteristics
Hyponatremia cohort (N = 279) 
N (%)





















Table 2. Specific patients’ characteristics for the hyponatremia cohort. Abbreviations. IQR: interquartile range; 
SIADH: syndrome of inappropriate antidiuretic hormone secretion; NA: not available.
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Results of the Cox proportional hazards regression model when testing the role of specific covariates 
in the hyponatremia cohort are shown in Supplementary Table S4. In particular, only the grade of hypona-
tremia was associated with survival (P = 0.02), with an incremental risk for death for mild (HR, 1.61; 95% CI, 
Figure 1. Kaplan-Meier curves for overall survival. Red lines indicate patients in the control cohort while green 
lines indicate patients in the hyponatremia cohort. Thick lines indicate raw survival curves while thin lines 
indicate adjusted survival curves. Patients in the control cohort had higher overall survival compared to patients 
in the hyponatremia cohort.
Figure 2. Kaplan-Meier curves for overall survival regarding the four most represented histologies. Red lines 
indicate patients in the control cohort while green lines indicate patients in the hyponatremia cohort. Thick 
lines indicate raw survival curves while thin lines indicate adjusted survival curves. Patients in the control 
cohort had higher overall survival compared to patients in the hyponatremia cohort in colorectal cancer (CRC, 
panel A), non-small cell lung cancer (NSCLC, panel B) and breast cancer (BC, panel C). In gastroesophageal 
cancer (GEC, panel D), adjusted model indicates that patients in the hyponatremia cohort had a better 
prognosis than patients in the control cohort.
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1.32–1.97), moderate (HR, 1.87; 95% CI, 1.25–2.78) and profound hyponatremia (HR, 2.29; 95% CI, 1.17–4.50) 
(Supplementary Figure S2). We found no survival differences in patients with normalized or not normalized 
serum sodium levels at discharge (Supplementary Table S4).
Development and validation of a nomogram including hyponatremia. In order to exploit the 
prognostic role of hyponatremia for a better risk-stratification of patients with advanced solid tumors, we devel-
oped a nomogram scoring system to predict the early (3-months) and late (36-months) OS probabilities.
According to the multivariable model, the presence of hyponatremia, age, ECOG PS, histology, liver, bone and 
brain metastases, number of previous lines of treatment, and the presence of calcium imbalances were used to 
develop the nomograms. The proportional hazards assumption was violated for hyponatremia and ECOG PS in 
a way that we could address by means of time stratification. The nomograms are shown in Fig. 3 and predict the 
probability that patients will be alive at 3 months and 36 months after the date of hospitalization. Supplementary 
Data S1 reports the model equations, which can be used for a more precise calculation of predictions. Patients 







71 vs 53a 1.36 1.20–1.55
ECOG PS
<0.001
1 vs 0 1.31 1.06–1.61 <0.01
2 vs 0 1.8 1.32–2.44 <0.001
3 vs 0 2.91 2.16–3.90 <0.001
4 vs 0 8.62 4.40–16.88 0.001
Histology
<0.001
NSCLC vs CRC 1.4 1.05–1.88 0.02
BC vs CRC 0.85 0.64–1.14 0.3
GEC vs CRC 1.75 1.27–2.39 <0.001
Melanoma vs CRC 1.52 1.04–2.22 0.03
PaC vs CRC 2.42 1.65–3.55 <0.001
BTC vs CRC 2.69 1.82–3.99 <0.001
RCC vs CRC 0.3 0.16–0.56 0.001
SCLC vs CRC 1.61 1.02–2.53 0.04
NET vs CRC 0.97 0.56–1.66 0.9
PC vs CRC 0.67 0.36–1.23 0.2
Other vs CRC 1.08 0.79–1.47 0.6
Liver metastases
<0.001
Yes vs No 1.7 1.43–2.02
Bone metastases
<0.001
Yes vs No 1.39 1.16–1.67
Brain metastases
<0.001
Yes vs No 1.74 1.32–2.28
Previous lines of treatment (N)
<0.001
1–2 vs 0 1.39 1.16–1.67 <0.001
>2 vs 0 1.59 1.26–2.02 <0.001
Days of hospitalization
0.005
9 vs 3a 1.13 1.04–1.23
Other electrolyte imbalances
 0.04
Calcium vs None 1.32 1.03–1.68 0.03
Potassium vs None 0.87 0.66–1.14 0.3
Both vs None 1.25 0.91–1.71 0.2
Harrell c-index Apparent: 0.75
Bias-corrected: 0.74
Table 3. Multivariable proportional hazard regression model on overall survival. Abbreviations. HR: hazard 
ratio; CRC: colorectal cancer; NSCLC: non-small cell lung cancer; BC: breast cancer; GEC: gastroesophageal 
cancer; PaC: pancreatic cancer; BTC: biliary tract cancer; RCC: renal cell carcinoma; SCLC: small-cell lung 
cancer; NET: neuroendocrine tumor; PC: prostate cancer. aThe two values are, respectively, the 3rd and 1st 
quartiles of the variable distribution.
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characteristics of the validation cohort are reported in Supplementary Table S5. When applied to the valida-
tion set, our nomogram scoring system confirmed its discriminative ability for prognostic stratification 
(Supplementary Figure S3), even though the observed number of deaths exceeded the number of nomogram 
predicted deaths by around 50% (Ratio, 1.56; 95% CI, 1.22–1.98).
Discussion
Weighing the impact of hyponatremia on survival of patients with advanced solid tumors could improve their 
prognostic stratification and facilitate the process of treatment decision making. In this retrospective study, we 
investigated the prognostic impact of hyponatremia in a heterogeneous population of hospitalized patients with 
metastatic or relapsed solid tumors admitted to a tertiary medical oncology department in a two-years period.
We observed a prevalence of hyponatremia at admission in hospitalized metastatic cancer patients of 27.2%. 
Since we did not take into account hyponatremia emerging during patient hospitalization, nor hyponatremia 
occurring in out-patients or in non-metastatic patients, the prevalence of hyponatremia in our study was lower 
than reported in previous retrospective studies (38–63.7%)2,18–20. Hyponatremia was clearly associated with 
tumor histology, being more frequent in small cell lung cancer, prostate cancer and biliary tract cancer. In 
particular, the high prevalence of hyponatremia in biliary tract cancer is consistent with the incidence of this 
electrolyte alteration reported in clinical trials with different chemotherapy combinations26–29, suggesting that 
treatment-related adverse events might contribute to the high prevalence of hyponatremia in biliary tract cancer. 
Noteworthy, hyponatremic patients had worse ECOG PS, higher prevalence of other electrolyte imbalances and 
higher number of metastatic sites or disease burden, suggesting more compromised general status18. In our study, 
patients with hyponatremia had a significantly lower OS, with a median time of only 2 months versus 13.2 months 
observed in the control cohort. Hyponatremia also retained an independent negative prognostic role in the multi-
variable model (HR, 1.66; 95% CI, 1.38–2.01; P < 0.001), in line with the available literature6,19. A subgroup anal-
ysis for the four most prevalent tumor histologies confirmed the negative prognostic impact of hyponatremia for 
colorectal cancer, non-small cell lung cancer and breast cancer15,16,18, but not for gastroesophageal cancer, a tumor 
type for which evidence from the literature is scarce and conflicting30,31. Notably, we observed an incremental 
Figure 3. Nomograms predicting the survival probability within 3 months (panel A) and 36 months (panel B) 
after the date of hospitalization. Abbreviations. BC: breast cancer, BTC: biliary tract cancer, CRC: colorectal cancer, 
GEC: gastroesophageal cancer, mos: months, NET: neuroendocrine tumor, NSCLC: non-small cell lung cancer, 
PaC: pancreatic cancer, PC: prostate cancer, RCC: renal cell carcinoma, SCLC: small-cell lung cancer, tx: therapy.
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death risk when stepping from mild to moderate and severe hyponatremia, thus confirming previously published 
data11,19,20 (Supplementary Figure S2, panel A).
Even if hyponatremia was reported to influence OS mainly within 6 months, it also retained its prognostic role 
at later time points, as previously shown in colorectal cancer16. Moreover, in our externally-validated nomogram 
scoring system, hyponatremia showed a remarkable weight both on 3-months and 36-months OS probabili-
ties. Especially, in our 36-months model, ECOG PS failed to show a relevant influence on survival and was not 
included in the nomogram. Remarkably, our nomogram scoring system could be easily used to facilitate the pro-
cess of treatment decision making based on life-expectancy of heavily-pretreated cancer patients (e.g. inclusion 
in clinical studies vs best supportive care). Regarding the higher number of observed death events relative to the 
number of nomogram predicted deaths in the validation cohort, it might be probably due to referral patterns. 
Although hyponatremia has been associated with critical conditions32, our findings indicate that hyponatremia 
may worsen the prognosis of metastatic cancer patients independently from patients’ general status. Interestingly, 
hyponatremia has been associated with worse PFS and lower response to treatment of cancer patients13,15,17,18,33, 
thus suggesting a possible, direct impact on cancer progression and/or resistance to treatments. For example, even 
if transient, hyponatremia activates the rennin–angiotensin–aldosterone system that is implicated in malignant 
transformation and cancer cell survival34–37. Hyponatremia could also interfere with the regulation and activity 
of sodium channels and sodium-involving ion pumps (e.g. voltage-gated sodium channels and epithelial sodium 
channel), whose aberrant expression has been found in multiple cancer types, directly contributing to cancer 
development and progression38–41. Furthermore, low sodium levels could stabilize or enhance via hypotonic stress 
the transcription of the glucocorticoid-induced protein kinase 1 (SGK1), which has been recently linked to cancer 
cell metastatization42,43.
Taken together and corroborated by our findings, these data imply that hyponatremia could have a pleiotropic 
action in cancer promotion and progression, thus explaining its unfavorable prognostic role in metastatic cancer 
patients beyond the traditional association with poorer patient performance status or tumor burden. Our study 
has some limitations: 1) it is a retrospective study (even if it relies on a prospective departmental registry) and 
we believe that a prospective study could be the ideal strategy to definitely validate the prognostic role of hypon-
atremia in patients with advanced malignancies; 2) we only included hospitalized patients, while extending a 
comprehensive assessment of the prognostic role of hyponatremia also in an out-patient setting would improve 
the solidity and reproducibility of our findings; 3) despite an external validation, our nomogram scoring system 
needs to be further tested for non–hospitalized metastatic cancer patients.
In conclusion, our study clearly confirmed the prognostic role of hyponatremia and weighed its impact on 
the OS of hospitalized patients with metastatic solid tumors. Based on our findings, serum sodium assessment 
could be exploited to design integrated prognostic tools, at least for hospitalized patients. A strong clinical and 
translational effort is needed to characterize the biological role of extracellular sodium levels and the interplay 
with ion channels located on tumor cell membranes in promoting cancer initiation, progression and resistance 
to treatment.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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